CRISPR Therapeutics
CRSP
135 hedge funds and large institutions have $855M invested in CRISPR Therapeutics in 2018 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 34 increasing their positions, 26 reducing their positions, and 12 closing their positions.
442% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 12
192% more capital invested
Capital invested by funds: $293M → $855M (+$562M)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
63% more funds holding
Funds holding: 83 → 135 (+52)
31% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 26
9.37% more ownership
Funds ownership: 30.47% → 39.84% (+9.4%)
72% less call options, than puts
Call options by funds: $8.4M | Put options by funds: $30.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
+$190M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$38M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$19.7M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$18.2M |
| 5 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$13.6M |
| 2 |
GTP
Global Thematic Partners
New York
|
-$11.6M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$8.82M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$6.6M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$3.52M |
CRSP Hedge Fund Activity: Q1 2018 in Review
135 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q1 2018, worth a combined $855M — up 192% from $293M a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new CRSP positions and 12 closed out — a net gain of 53 holders — while 34 added to existing stakes and 26 trimmed.
The largest buyer was Versant Venture Management, opening a new position worth an estimated $190M. The largest seller was Clough Capital Partners, cutting an estimated $13.6M.
- 135 institutional investors held CRISPR Therapeutics (CRSP) as of Q1 2018, up from 83 in Q4 2017.
- Funds reported $855M of CRISPR Therapeutics stock for Q1 2018, up 192% quarter-over-quarter.
- 65 funds opened new CRISPR Therapeutics positions in Q1 2018 and 12 closed out, a net change of +53 holders.
- The largest CRISPR Therapeutics buyer in Q1 2018 was Versant Venture Management, an estimated $190M added.
- The largest CRISPR Therapeutics seller in Q1 2018 was Clough Capital Partners, an estimated $13.6M sold.
Based on aggregated 13F filings for Q1 2018.